WHAT IS EVIDENCE BASED PRACTICE?
The most common definition of EBP is taken from Dr. David Sackett, a pioneer in evidence-based practice. EBP is "the conscientious, explicit and judicious use of current best evidence in making decisions about the care of the individual patient. It means integrating individual clinical expertise with the best available external clinical evidence from systematicresearch." (Sackett D, 1996)
EBP is the integration of clinical expertise, patient values, and the best research evidence into the decision making process for patient care. Clinical expertise refers to the clinician's cumulated experience, education and clinical skills. The patient brings to the encounter his or her own personal and unique concerns, expectations, and values. The best evidence is usually found in clinically relevant research that has been conducted using sound methodology. (Sackett D, 2002)
Healthcare data are increasingly collected in transactional systems such as electronic health records (EHRs) and aggregated into analytical systems such as clinical data warehouses (
To assess whether the gender (primary) and geographical affiliation (post-hoc) of the first and/or last authors are associated with publication decisions after peer review.
Case-control study.
Biomedical journals.
Original peer-reviewed manuscripts submitted between 1 January 2012 and 31 December 2019.
Manuscripts accepted (cases) and rejected for publication (controls).
Of 6213 included manuscripts, 5294 (85.2%) first and 5479 (88.1%) last authors’ gender were identified; 2511 (47.4%) and 1793 (32.7%) were women, respectively. The proportion of women first and last authors was 48.4% (n=1314) and 32.2% (n=885) among cases and 46.4% (n=1197) and 33.2% (n=908) among controls. After adjustment, the association between the first author’s gender and acceptance for publication remained non-significant 1.04 (0.92 to 1.17). Acceptance for publication was lower for first authors affiliated to Asia 0.58 (0.46 to 0.73), Africa 0.75 (0.41 to 1.36) and South America 0.68 (0.40 to 1.16) compared with Europe, and for first author affiliated to upper-middle country-income 0.66 (0.47 to 0.95) and lower-middle/low 0.69 (0.46 to 1.03) compared with high country-income group. It was significantly higher when both first and last authors were affiliated to different countries from same geographical and income groups 1.35 (1.03 to 1.77), different countries and geographical but same income groups 1.50 (1.14 to 1.96) or different countries, geographical and income groups 1.78 (1.27 to 2.50) compared with authors from similar countries. The study funding was independently associated with the acceptance for publication (when compared with no funding, 1.40; 1.04 to 1.89 for funding by association & foundations, 2.76; 1.87 to 4.10 for international organisations, 1.30; 1.04 to 1.62 for non-profit & associations & foundations). The reviewers’ recommendations of the original submitted version were significantly associated with the outcome (unadjusted 5.36; 4.98 to 5.78 for acceptance compared with rejection). Gender of the first author was not associated with reviewers’ recommendations (adjusted 0.96, 0.87 to 1.06).
We did not identify evidence of gender bias during the editorial decision-making process for papers sent out to peer review. However, the under-representation in manuscripts accepted for publication of first authors affiliated to Asia, Africa or South America and those affiliated to upper/lower-middle and low country-income group, indicates poor representation of global scientists’ opinion and supports growing demands for improving equity, diversity and inclusion in biomedical research. The more diverse the countries and incomes of the first and last authors, the greater the chances of the publication being accepted.
The objective of this study is to analyse the perspectives of screening candidates and healthcare professionals on shared decision-making (SDM) in prostate cancer (PCa) screening using the prostate-specific antigen (PSA) test.
Descriptive qualitative study (May–December 2022): six face-to-face focus groups and four semistructured interviews were conducted, transcribed verbatim and thematically analysed using ATLAS.ti software.
Data were obtained as part of the project PROSHADE (Decision Aid for Promoting Shared Decision Making in Opportunistic Screening for Prostate Cancer) to develop a tool for SDM in PCa screening with PSA testing in Spain.
A total of 27 screening candidates (three groups of men: 40–50 years old; 51–60 years old and 61–80 years old), 25 primary care professionals (one group of eight nurses and two groups of physicians: one with more and one with less than 10 years of experience), and four urologists. Focus groups for patients and healthcare professionals were conducted separately.
Participants' perceptions of shared decision-making related to PSA opportunistic screening, including their understanding, preferences, and attitudes.
Three themes were generated: (1) perceptions of SDM, (2) perceptions of PSA testing and (3) perceptions of SDM regarding PCa screening. Theme 1: screening candidates valued SDM when it included clear information and empowered them. There was consensus with primary care health professionals on this point, although their knowledge and implementation of SDM varied. Theme 2: candidates were divided on PSA testing; some trusted it for early detection, while others expressed scepticism due to concerns about false positives and invasive procedures, reflecting gaps in accessible information. Theme 3: professionals across primary and specialised care stressed the need for standardised SDM protocols. Primary care physicians were particularly concerned that PSA decisions align with scientific evidence and urologists recognised SDM as valuable in PSA testing only if it was adequately explained to each patient. Barriers to implementing SDM included insufficient coordination across care levels, lack of consensus-driven protocols and limited clinical time.
While patients expect comprehensive information, primarily based on practice to achieve empowerment, healthcare professionals face obstacles such as limited time and insufficient coordination between primary care and urology. All stakeholders agree on the importance of evidence-based tools to reinforce effective SDM and enhance collaboration across urologists and primary care in the context of PSA testing.